ArticleLeukemia2024

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.

Christine E Birdwell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.